---
schema_version: "secwatch.filing_event.v1"
accession: "0001356576-23-000040"
form_type: "8-K"
ticker: "SUPN"
cik: "0001356576"
company_name: "SUPERNUS PHARMACEUTICALS, INC."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T17:46:03.062101+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Supernus settles Oxtellar XR patent litigation with Apotex; generic entry allowed Sep 1, 2024

## Summary
- Settlement resolves patent litigation with Apotex over generic Oxtellar XR (oxcarbazepine ER).
- Apotex granted license to market generic version in U.S. beginning September 1, 2024.
- Supernus retains right to market an authorized generic product itself or through third parties.
- All claims and counter-claims in the patent litigation will be dismissed.

## SEC filing metadata
- accession: 0001356576-23-000040
- form_type: 8-K
- ticker: SUPN
- cik: 0001356576
- company_name: SUPERNUS PHARMACEUTICALS, INC.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000040/0001356576-23-000040-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000040/supn-20230621.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001356576-23-000040
- JSON: https://secwatch.observer/filing/0001356576-23-000040.json
- Plain text: https://secwatch.observer/filing/0001356576-23-000040.txt

## Key facts
- Material Agreements
  SUPERNUS PHARMACEUTICALS, INC. entered into Settlement and License Agreements with Apotex Inc. and Apotex Corp. (collectively, "Apotex") (effective 2023-06-21).
  - Action: entry
  - Agreement: settlement
  - Counterparty: Apotex Inc. and Apotex Corp. (collectively, "Apotex")
  - Effective: 2023-06-21
  source text: On June 21, 2023, Supernus Pharmaceuticals, Inc. ("Supernus" or the "Company") entered into Settlement and License Agreements (the "Agreements) with Apotex Inc. and Apotex Corp. (collectively, "Apotex"), to settle ongoing patent litigation regarding Apotex's filing of an Abbreviated New Drug Application ("ANDA") seeking approval to market a generic version of the Company's Oxtellar XR ® (oxcarbazepine) extended-release tablets.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1356576/000135657623000040/0001356576-23-000040-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.